Precision’s allogeneic CAR T efficacy builds, along with safety questions

There’s a growing population of CAR T-relapsed patients that Precision Biosciences is aiming to treat, but its latest data highlight the safety challenges of treating the patient population with a second CAR T cell therapy.

On Wednesday, the company reported improved response rates and durability data from a Phase I/II study of its lead allogeneic CAR T cell candidate, PBCAR0191, since it last reported results at the American Society of Hematology (ASH) conference in December...